• ABOUT
    Overview
    Explore the legacy and impact of Amgen, a pioneering biotechnology firm revolutionizing medicine through innovative biological drugs and cutting-edge research.
    Amgen History
    Mission & Values
    Amgen's mission is to harness the potential of science and biotechnology to develop life-saving therapies, guided by values like ethics, teamwork, and quality.
    Cantact Us
    Connect with Amgen China for inquiries and assistance.
  • SCIENCE
    Science
    Discover how Amgen's innovations in biotechnology are shaping the future of medicine. Explore our pioneering role in advancing science to transform lives.
  • PRODUCT
    Products
    Discover Amgen's array of innovative prescription drugs aimed at treating serious illnesses. Explore our impactful therapies dedicated to improving lives.
    Global Patients Safety
    China Medical Info
  • RESPONSIBILITY
    Responsibility
    Amgen strives to make a difference through the Foundation, environmental initiatives, ethics, and more. Discover our impactful programs and achievements.
    Amgen and the Amgen Foundation
Newsroom
Careers
简体中文
Newsroom Careers 简体中文
Main Menu
ABOUT
  • Overview
    Explore the legacy and impact of Amgen, a pioneering biotechnology firm revolutionizing medicine through innovative biological drugs and cutting-edge research.
  • Amgen History
  • Mission & Values
    Amgen's mission is to harness the potential of science and biotechnology to develop life-saving therapies, guided by values like ethics, teamwork, and quality.
  • Contact Us
    Connect with Amgen China for inquiries and assistance.
Main Men
SCIENCE
  • Science
    Discover how Amgen's innovations in biotechnology are shaping the future of medicine. Explore our pioneering role in advancing science to transform lives.
Main Men
PRODUCTS
Main Men
RESPONSIBILITY
Home
箭头
Newsroom
箭头
Press Release

Press Release

Jul 24, 2023
2023 Tsinghua Amgen Scholars Program Kicks Off
Aug 31, 2022
Amgen Foundation and Tsinghua University Join Forces to Launch Amgen Biotechnology Experience in Mainland China
Jun 27, 2022
Amgen and Fosun Pharma Announce Collaboration to Accelerate Two Innovative Medicines Benefitting Chinese Patients
Nov 10, 2021
Amgen Enters into Strategic Collaboration with Profex to Co-promote Prolia® in China Broad Market
Sep 17, 2020
Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies
Jun 19, 2020
Amgen Receives National Medical Products Administration Approval For Prolia® (Denosumab) in Chin
Apr 30, 2020
Amgen Reports First Quarter 2020 Financial Results
Apr 2, 2020
Amgen and Adaptive Biotechnologies Announce Strategic partnership to develop A therapeutic TO prevent or treat COVID-19
Mar 23, 2020
Amgen and the Amgen Foundation Commit Up to $12.5 Million to Support COVID-19 Relief Efforts
Nov 22, 2019
Program of Building of High-Quality and Efficient Health Service System and Empirical Study in the Context of Aging Kicked off in Beijing
Oct 31, 2019
Amgen Enters into Strategic Collaboration with Beigene to Expand Oncology Presence in China
Sep 26, 2019
Nearly 80% of Chinese Heart Attack Survivors Underestimate the Importance of High Cholesterol Management
Sep 8, 2019
Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Larger Patient Group At WCLC 2019
May 24, 2019
Amgen Receives Approval For XGEVA® (Denosumab) in China As The First Medicine To Treat Giant Cell Tumor Of Bones (GCTB)
Jan 24, 2019
Amgen Receives NMPA Approval For Repatha® (evolocumab) In China To Reduce The Risk Of Cardiovascular Events
Sep 18, 2018
China Charity Federation Launches Repatha® Patient Assistance Program
Aug 8, 2018
Amgen's Repatha® (evolocumab) Receives Approval In China As The First PCSK9 Inhibitor For The Treatment Of Homozygous Familial Hypercholesterolemia
Mar 23, 2018
Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (Evolocumab) Prevents Heart Attacks And Strokes
Sep 26, 2017
Amgen And Simcere Announce Strategic Collaboration To Co-Develop And Commercialize Biosimilars In China
Sep 20, 2017
Amgen Foundation Launches Amgen Biotech Experience In China
Jul 26, 2017
Amgen-Peking University Study Published in Cell Reveals Why Some T Cells Fail to Fight Cancer
Aug 27, 2015
FDA Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab)
Jul 21, 2015
European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol
May 22, 2015
Amgen Receives Positive CHMP Opinion For Use Of Repatha™ (Evolocumab) For The Treatment Of High Cholesterol
Mar 1, 2015
Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma
Dec 3, 2014
BLINCYTO is the First-and-Only Bispecific CD19-Directed CD3 T-Cell Engager (BiTE®) Immunotherapy to be Approved by the FDA
Nov 17, 2014
Amgen Opens Asia Research and Development Center and Establishes Integrated Research and Development Capacity in China
Oct 9, 2014
Amgen's BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia
Aug 4, 2014
Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In Patients With Relapsed Multiple Myeloma Met Primary Endpoint
Sep 26, 2013
Betta Pharma and Amgen Announce Approval to Establish Planned Joint Venture
Sep 24, 2013
Amgen and ShanghaiTech University Announce Plans for Amgen China R&D Center to Open on ShanghaiTech Campus
Aug 7, 2013
Amgen Launches Post-Doctoral Fellowship Program in China
May 9, 2013
Amgen and Zhejiang Beta Pharma Announce Planned Joint Venture in China
1 2 3
Do you want to link to other

websites and leave Amgen.cn?

NO, RETURN TO AMGEN.CN YES, LEAVE AMGEN.CN
You are now leaving Amgen China website.

Amgen China takes no responsibility for the information contained on the Amgen international server or site which you will be accessing. The information you are about to access may not comply with the China regulatory environment.